First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis

Public Health Action

Volumn 4, Issue , 2014, Pages S17-S23

  Alikhanova, Natavan ^a   Akhundova, I ^a   Seyfaddinova, M ^a   Mammadbayov, E ^a   Mirtskulava, V ^b   Rusch Gerdes S ^c   Bayramov, R ^d   Suleymanova, J ^e   Kremer, K ^f   Dadu, A ^f   Acosta, C D ^f   Harries, A D ^g,h   Dara, M ^f  

^a Scientific Research Institute of Lung Disease   (Azerbaijan)

^b TADR Test and Evaluation   (United States)

^c Forsungszentrum Borstel   (Germany)

^d AZERBAIJAN MEDICAL UNIVERSITY   (Azerbaijan)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^g International Astronomical Union   (France)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Azerbaijan; Drug resistant tuberculosis; Operational research; SORT IT; Surveillance

Indexed keywords

AMIKACIN; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE CONTROL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEALTH SURVEY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PUBLIC HEALTH SERVICE; QUESTIONNAIRE; RECURRENCE RISK; RISK FACTOR; SOCIAL STATUS; TREATMENT FAILURE; TUBERCULOSIS;

EID: 85019462873     PISSN: None     EISSN: 22208372     Source Type: Journal    
DOI: 10.5588/pha.14.0049     Document Type: Article

References (20)

1. World Health Organization. The Global MDR-TB and XDR-TB Response Plan 2007-2008. WHO/HTM/TB/2007.387. Geneva, Switzerland: WHO, 2007.
2. World Health Organization. Roadmap to prevent and combat drug-resistant tuberculosis. The Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region, 2011-2015. Copenhagen, Denmark: WHO, 2011.
3. World Health Organization. Tuberculosis prevalence surveys: a handbook, 2011. WHO/HTM/TB.2010.17. Geneva, Switzerland: WHO, 2010.
4. World Health Organization. Anti-tuberculosis drug resistance in the world. 4th ed. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
5. Zignol M, Dara M, Dean A S, et al. Drug-resistant tuberculosis in the WHO European Region: Meta-analysis of surveillance data. Drug Resistance Updates 2013; 16: 108-115. http://dx.doi.org/10.1016/j.drup.2014.02.003
6. World Health Organization. Global tuberculosis report 2013. WHO/HTM/ TB/2013.11. Geneva, Switzerland: WHO, 2013.
7. von Elm E, Altman D G, Egger M, Pocock S J, Gøtzsche P C, Vandenbroucke J P; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-349.
8. Edginton M, Enarson D, Zachariah R, et al. Why ethics is indispensible for good-quality operational research. Public Health Action 2012; 2: 21-22.
9. Pfyffer G E, Strässle A, van Gorkum T, et al. Multidrug-resistant tuberculosis in prison inmates, Azerbaijan. Emerging Infect Dis 2001; 7: 855-861.
10. Ruddy M, Balabanova Y, Graham C, et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax 2005; 60: 130-135.
11. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006; 10: 402-408.
12. Temple B, Ayakaka I, Ogwang S, et al. Rate and amplification of drug resistance among previously treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis 2008, 47: 1126-1134.
13. van der Werf M J, Langendam M W, Huitric E, Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 2012; 39: 1511-1519.
14. Andrews J R, Shah N S, Weissman D, Moll A P, Friedland G, Gandhi N R. Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PLOS ONE 2010; 5: e15735
15. Diande S, Sangare L, Kouanda S, et al.: Risk factors for multidrug-resistant tuberculosis in four centers in Burkina Faso, West Africa. Mikrob Drug Resist 2009, 15: 217-221.
16. Faustini A, Hall A J, Perucci C A: Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006; 61: 158-163.
17. Casal M, Vaquero M, Rinder H, et al. A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. Microb Drug Resist 2005, 11: 62-67.
18. Weyer K, Brand J, Lancaster J, Levin J, van der Walt M. Determinants of multidrug- resistant tuberculosis in South Africa: results from a national survey. S Afr Med J 2007, 97: 1120-1128.
19. Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-1505.
20. World Health Organization Regional Office for Europe. Best practices in prevention control and care for drug-resistant tuberculosis, 2013. Copenhagen, Denmark: WHO, 2013.